Trial results

RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.

NCT07301437 on ClinicalTrials.gov · last registry update 2026-03-23

Registered but not yet open, with 120 participants planned. Due to report 31 August 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: weight loss. Sponsors move these dates routinely; any movement since this site started watching is listed below. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

NOT_YET_RECRUITING

Phase

P4

Drug

liraglutide

Victoza, Xultophy, Saxenda

Sponsor

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Sponsor type

Other

Enrollment

120

Started

2026-05-01

Primary completion

2027-08-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

weight loss

Conditions studied

Overweight and Obese Adults

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.